Oncoscience
Overview
Oncoscience is a scientific journal, published since 2013 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
Oncoscience
Start
2013
End
Continuing
e-ISSN
2331-4737
Country
United States
Language
English
Specialty
Oncology
Recent Articles
1.
Devalla A, Mangla M, Ramavath K, Prabhala S, Kumar N, Jarathi A
Oncoscience
. 2025 Feb;
12:21-25.
PMID: 39931074
Postmenopausal bleeding (PMB) with a diffusely enlarged uterus necessitates Magnetic Resonance Imaging (MRI) to reach an accurate diagnosis. Adenomyosis, especially extensive glandular variant, is an extremely rare cause reported in...
2.
Kalfoutzou A, Spanou K, Mylonakis A, Lagopoulou V, Dimitrakoudi M, Korovila A, et al.
Oncoscience
. 2025 Feb;
12:13-20.
PMID: 39911853
Systemic mastocytosis (SM) encompasses a wide spectrum of myeloproliferative disorders defined by the aggregation of abnormal mast cells in various tissues, including the bone marrow, gastrointestinal tract, liver and lymph...
3.
Seah H, Bade V, Potluri L, Talluri S, Prabhala R
Oncoscience
. 2025 Jan;
12():1-2.
PMID: 39839313
No abstract available.
4.
Samuels A, Badeghiesh A, Baghlaf H, Dahan M
Oncoscience
. 2025 Jan;
12():3-12.
PMID: 39839312
Importance: Cervical cancer is the fourth most common cancer among women globally and a significant cause of cancer-related deaths. Understanding the impact of cervical cancer diagnosed during pregnancy on maternal,...
5.
Cherkasova V, Kovalchuk O, Kovalchuk I
Oncoscience
. 2024 Nov;
11:99-105.
PMID: 39534512
Chemotherapy is a therapy of choice for many cancers. However, it is often inefficient for long-term patient survival and is usually accompanied by multiple adverse effects. The adverse effects are...
6.
Costa M, Magalhaes H
Oncoscience
. 2024 Oct;
11:92-98.
PMID: 39381773
Approximately 20% of lung cancer patients have brain metastasis at diagnosis, which is associated with a worse prognosis and a negative impact on quality of life. The emergence of new...
7.
Huang Y, Chen S, Yao N, Lin S, Zhang J, Xu C, et al.
Oncoscience
. 2024 Sep;
11:69-91.
PMID: 39318358
Poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi) are the first-approved anticancer drug designed to exploit synthetic lethality. PARPi selectively kill cancer cells with homologous recombination repair deficiency (HRD), as a result,...
8.
9.
10.
Puvvula P, Johnson A, Bernal-Mizrachi L
Oncoscience
. 2024 Jul;
11:58-64.
PMID: 39015604
No abstract available.